An experimental Acceleron drug for a blood disorder has hit the main goals of a pivotal study, and the company and partner Celgene say they now plan to file for FDA approval next year.
The Acceleron (NASDAQ: XLRN) drug, luspatercept, is being tested as a treatment for myelodysplastic syndrome (MDS), a type of cancer characterized by abnormally formed or improperly functioning blood cells. According to the American Cancer Society, the disorder typically causes anemia-a shortage of red blood cells.
Luspatercept is an injectable, protein-based drug that is believed to regulate the late-stage maturation of red blood cells. The drug… Read more »
UNDERWRITERS AND PARTNERS